# Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification

> **NCT03832179** · PHASE4 · COMPLETED · sponsor: **Bay Area Retina Associates** · enrollment: 16 (actual)

## Conditions studied

- Diabetic Macular Edema
- Cataract

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Ranibizumab
- **DRUG:** Aflibercept
- **DRUG:** Ozurdex

## Key facts

- **NCT ID:** NCT03832179
- **Lead sponsor:** Bay Area Retina Associates
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-15
- **Primary completion:** 2023-09-01
- **Final completion:** 2024-03-30
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-09-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03832179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03832179, "Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03832179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*